Ishikawa Masatomo, Sakata Muneyuki, Ishii Kenji, Kimura Yuichi, Oda Keiichi, Toyohara Jun, Wu Jin, Ishiwata Kiichi, Iyo Masaomi, Hashimoto Kenji
Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, Chiba, Japan.
Int J Neuropsychopharmacol. 2009 Sep;12(8):1127-31. doi: 10.1017/S1461145709990204. Epub 2009 Jul 2.
The acetylcholinesterase (AChE) inhibitor donepezil is also a sigma1 receptor agonist. We examined whether donepezil binds to sigma1 receptors in the living human brain after a single oral administration. Dynamic positron emission tomography (PET) data acquisition using the selective sigma1 receptor ligand [11C]SA4503 was performed to evaluate quantitatively the binding of [11C]SA4503 to sigma1 receptors in eight healthy male volunteers. Each subject had a PET scan before and after receiving a single dose of donepezil (5 or 10 mg). The binding potential of [11C]SA4503 was calculated. Doses of 5 mg and 10 mg donepezil bound to sigma1 receptors in the human brain with occupancies of approximately 60% and approximately 75%, respectively, in a dose-dependent manner. This study demonstrated that donepezil binds to sigma1 receptors in the living human brain at therapeutic doses. Therefore, sigma1 receptors may be implicated in the pharmacological mechanism of donepezil in the human brain.
乙酰胆碱酯酶(AChE)抑制剂多奈哌齐也是一种σ1受体激动剂。我们研究了单次口服给药后多奈哌齐是否能在活体人脑中与σ1受体结合。使用选择性σ1受体配体[11C]SA4503进行动态正电子发射断层扫描(PET)数据采集,以定量评估[11C]SA4503在8名健康男性志愿者脑中与σ1受体的结合情况。每位受试者在接受单次剂量的多奈哌齐(5或10毫克)之前和之后都进行了PET扫描。计算了[11C]SA4503的结合潜能。5毫克和10毫克剂量的多奈哌齐在人脑中与σ1受体结合,占有率分别约为60%和约75%,呈剂量依赖性。这项研究表明,治疗剂量的多奈哌齐能在活体人脑中与σ1受体结合。因此,σ1受体可能参与了多奈哌齐在人脑中的药理机制。